Lung Cancer

Given their proximity to both patients and information, lung cancer advocacy groups are in a good position to help better educate patients and physicians about the benefits of biomarker testing.

Many patients with lung cancer may experience side effects, such as fatigue and shortness of breath, that can prevent them from exercising. However, for the first time, new research findings showed benefits from exercise in those with advanced disease.

The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.

With the click of a button, patients can pave the way for lung cancer research, too.

Here are the top 5 CURE stories for October 2018.

The immunotherapy agent received approval for the treatment of metastatic squamous non-small cell lung cancer.

A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.

Patients with head and neck cancer appeared to be receptive to lung cancer screening, according to recent research performed at the University of Iowa Hospitals and Clinics.

As marijuana use continues to increase across the US – and become legalized in more states – understanding the potential negative health effects is paramount.

Patients with the disease reported increased feelings of stigmatization, and results also showed that patients are viewed or treated differently than those with other cancer types.

Long-term opioid use is more prevalent among patients treated with invasive surgical techniques for early-stage non-small cell lung cancer than those who undergo minimally-invasive surgery.

While the living rooms take place in the ALCF's California headquarters, people around the world can tune in to the live stream, where they can participate and ask questions as if they were actually there.

The Food and Drug Administration (FDA) has approved Vizimpro (dacomitinib) for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI).

The IMpower133 trial demonstrated the added overall and progression-free survival benefits of adjuvant Tecentriq with standard of care therapy for patients with extensive-stage small cell lung cancer.

In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory and anxiety.

Patient-caregiver communities focused on non-small cell lung cancer with genomic alterations offer support, awareness and education to help accelerate research in this space.

With new therapies that can target specific genetic mutations in patients with lung cancer, testing the tumor’s makeup is becoming increasingly important, according to Joshua Bauml, M.D.

From an inaugural gathering in 2009 that attracted approximately 700 people, the Life and Liberty event has grown in size each year, with more than 4,000 patients in attendance at last September’s celebration. Organizers said about 6,000 were there this year.

An expert discusses tips on how patients with cancer can manage their "scanxiety."

The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.

After success in the non-small cell lung cancer space, immunotherapy is finally making waves in the treatment of small cell lung cancer.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

The researchers found that the trial that led to the guidelines – which recommend screening based on age and smoking history – did not include fair representation from all groups across the nation.

Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.